Βιβλιογραφία 1. Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid composition of different regions of the brain during aging. J Neurochem 1990; 54: 415-423 2. Greenberg S, Frishman WH. Co-enzyme Q10: A new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596-608 3. Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Invest 1993; 71: 129-133 4. Mortensen SA. Perspectives on therapy of cardiovascular disease with co-enzyme Q10. Clin Invest 1993; 71: 116-123 5. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of co-enzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 65: 521-523 6. Khatta M, Alexander BS, Kritchen CM, et al. The effect of co-enzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132: 636-640 7. Sinatra ST. Refractory congestive heart failure successfully managed with high dose co-enzyme Q10 administration. Mol Aspects Med 1997; 18: S299-S305 8. Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with co-enzyme Q10. Biochem Biophys Res Commun 1993; 192: 241-245 9. Lockwood K, Moesgaard S, Hanioka T. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995; 212: 172-177 10. Weston SB, Zhou S, Weatherby RP, et al. Does exogenous co-enzyme Q 10 affect aerobic capacity in endurance athletes? Int J Sports Nutr 1997; 7: 197-206 11. Malm C, Svensson M, Ekblom B, et al. Effects of udiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997; 161: 370-384 12. Shultz CW, Beel MF, Fontaine D, et al. Absorption tolerability and effects on mitochondrial activity of oral co-enzyme Q10 in parkinsonian patients. Neurology 1998; 50: 793-795 13. Spigset O. Reduced effect of warfarin caused by ubidecarone. Lancet 1994; 344: 1372-1373
220